Michael E. Petrone

518 total citations
27 papers, 403 citations indexed

About

Michael E. Petrone is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael E. Petrone has authored 27 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 7 papers in Genetics and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael E. Petrone's work include Acute Myeloid Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Cancer Treatment and Pharmacology (5 papers). Michael E. Petrone is often cited by papers focused on Acute Myeloid Leukemia Research (14 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Cancer Treatment and Pharmacology (5 papers). Michael E. Petrone collaborates with scholars based in United States, Australia and Italy. Michael E. Petrone's co-authors include Thomas J. McKearn, Fabio Calabrò, Daniel P. Petrylak, Nicholas D. James, Peter Harper, S. Falcon, William Berry, Martine George, Oliver Sartor and Manfred Wirth and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Michael E. Petrone

25 papers receiving 391 citations

Peers

Countries citing papers authored by Michael E. Petrone

Since Specialization

Citations

This map shows the geographic impact of Michael E. Petrone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Petrone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Petrone more than expected).

Fields of papers citing papers by Michael E. Petrone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Petrone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Petrone. The network helps show where Michael E. Petrone may publish in the future.

Co-authorship network of co-authors of Michael E. Petrone

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Petrone. A scholar is included among the top collaborators of Michael E. Petrone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Petrone. Michael E. Petrone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients 2018 ·Blood ·Shyamala Navada, Guillermo Garcia‐Manero, Ehab Atallah, (unknown), Jamile M. Shammo, Elizabeth A. Griffiths, Samer K. Khaled, Shaker R. Dakhil, David Young, Rosalie Odchimar-Reissig, Naveen Pemmaraju, Yesid Alvarado, Maro Ohanian, (unknown), (unknown), Manoj Maniar, Michael E. Petrone, Steven Fruchtman, Lewis R. Silverman	10
2	Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials 2018 ·Blood ·Manoj Maniar, Chen Ren, (unknown), Michael E. Petrone, Steven Fruchtman, David R. Taft	1
3	A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia 2017 ·Leukemia Research ·Shyamala Navada, Steven Fruchtman, Rosalie Odchimar-Reissig, Erin P. Demakos, Michael E. Petrone, (unknown), James F. Holland, Lewis R. Silverman	35
4	Relationship of bone marrow blast (BMBL) response to overall survival (OS) in a multicenter study of rigosertib (Rigo) in patients (pts) with myelodysplastic syndrome (MDS) with excess blasts progressing on or after treatment with a hypomethylating agent (HMA). 2017 ·Journal of Clinical Oncology ·Aref Al‐Kali, Devendra Hiwase, Maria R. Baer, Peter L. Greenberg, Jake Shortt, Robert H. Collins, David P. Steensma, Amit Verma, Gail J. Roboz, Jamile M. Shammo, Oliver G. Ottmann, John F. Seymour, Jeff Szer, Wolfgang Meyer, (unknown), Michael E. Petrone, Steven Fruchtman, Guillermo Garcia‐Manero, Lewis R. Silverman	1
5	Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) 2016 ·Blood ·Guillermo Garcia‐Manero, Pierre Fenaux, Aref Al‐Kali, Shyamala Navada, Maria R. Baer, Azra Raza, Peter L. Greenberg, Karl‐Anton Kreuzer, Devendra Hiwase, Gail J. Roboz, Valeria Santini, Uwe Platzbecker, Michael E. Petrone, Bernard H. Brownstein, (unknown), Manoj Maniar, Lewis R. Silverman	4
6	Rigosertib in myelodysplastic syndromes (MDS) 2016 ·Expert Opinion on Orphan Drugs ·Azra Raza, Abdullah Mahmood Ali, M. V. Ramana Reddy, (unknown), Michael E. Petrone, Manoj Maniar, Ronald Feitosa Pinheiro, (unknown), Steven Fruchtman	2
7	Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study 2016 ·Blood ·Shyamala Navada, Guillermo Garcia‐Manero, (unknown), Rosalie Odchimar-Reissig, Erin P. Demakos, Yesid Alvarado, Naval Daver, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Pierre Fenaux, Michael E. Petrone, (unknown), Steven Fruchtman, Lewis R. Silverman	4
8	Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome. 2015 ·Journal of Clinical Oncology ·Lewis R. Silverman, Pierre Fenaux, Peter L. Greenberg, Erin P. Demakos, Valeria Santini, John F. Seymour, (unknown), Michael E. Petrone, (unknown), N. Azarnia, Guillermo Garcia‐Manero	1
9	Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy 2015 ·Expert Review of Pharmacoeconomics & Outcomes Research ·Christopher R. Cogle, Jesse D. Ortendahl, Tanya G. K. Bentley, (unknown), (unknown), Thomas J. McKearn, Michael E. Petrone, Sudipto Mukherjee	3
10	Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1st-Line Therapy 2014 ·Blood ·Christopher R. Cogle, Sudipto Mukherjee, Tanya G. K. Bentley, Michael S. Broder, Eunice Chang, (unknown), Thomas J. McKearn, (unknown), (unknown), Michael E. Petrone, Gordon H. Sun	4
11	Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies 2014 ·Blood ·Sudipto Mukherjee, Christopher R. Cogle, Tanya G. K. Bentley, Michael S. Broder, Eunice Chang, (unknown), Thomas J. McKearn, (unknown), (unknown), Michael E. Petrone, Gordon H. Sun	5
12	Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial 2009 ·Journal of Clinical Oncology ·Cora N. Sternberg, Daniel P. Petrylak, Oliver Sartor, J. Alfred Witjes, Tomasz Demkow, Jean-Marc Ferrero, Jean-Christophe Eymard, S. Falcon, Fabio Calabrò, Nicholas D. James, I. Bodrogi, Peter Harper, Manfred Wirth, William Berry, Michael E. Petrone, Thomas J. McKearn, Mojtaba Noursalehi, Martine George, Marcel Rozencweig	262
13	Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial 2009 ·Journal of Clinical Oncology ·Oliver Sartor, Daniel P. Petrylak, C. Sternberg, Fred Witjes, Susan Halabi, William Berry, Michael E. Petrone, (unknown), Mojtaba Noursalehi, (unknown)	1
14	Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect Study 2009 ·Clinical Cancer Research ·Alejandro D. Ricart, John Sarantopoulos, Emiliano Calvo, Quincy S. Chu, Douglas S. Greene, Faith E. Nathan, Michael E. Petrone, Anthony W. Tolcher, Kyriakos P. Papadopoulos	12
15	Phase I study of oral platinum with concurrent radiation therapy in non small cell lung cancer 2008 ·Journal of Clinical Oncology ·H. Choy, Randall Hughes, (unknown), (unknown), Michael E. Petrone, (unknown), (unknown), Joan H. Schiller	1
16	Phase I study of the effects of hepatic impairment on the pharmacokinetic (PK) and safety of satraplatin in patients with refractory non-hematologic cancer 2006 ·Journal of Clinical Oncology ·(unknown), Gavin Preston, Christopher B. Jones, John Sarantopoulos, T.E. Dufresne, Michael E. Petrone, Faith E. Nathan, Douglas S. Greene, Tiffany Anthony, (unknown)	2
17	Satraplatin: A new treatment option for patients with hormone refractory prostate cancer 2005 ·Journal of Clinical Oncology ·Faith E. Nathan, C. Sternberg, Oliver Sartor, Daniel P. Petrylak, Fred Witjes, Katja Wosikowski, Michael E. Petrone, Marcel Rozencweig	4
18	Comparison of The Pharmacokinetics and Safety of Metoclopramide, Nasal Spray Versus Orally Administered Metoclopramide Tablets, USP in Patients With Diabetic Gastroparesis 2003 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), Michael E. Petrone, (unknown), (unknown), Carol Braun Trapnell	1
19	Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation 2001 ·Experimental Hematology ·William J. Lane, Koichi Hattori, Sérgio Dias, Ellinor I.B. Peerschke, Malcolm A.S. Moore, (unknown), (unknown), Michael E. Petrone, Shahin Rafii	15
20	The Diagnosis of Dementia: Demographic Characteristics 1990 ·The Gerontologist ·(unknown), Harry Meade, Michael E. Petrone, Lotte Meinert, (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact